Patients with initially unresectable colorectal liver metastases benefit from certain induction therapies that increase surgical conversion potential.
- Bevacizumab plus triplet chemotherapy showed a 99% probability of improving R0-1 resection rates and progression-free survival.
- Bevacizumab plus doublet chemotherapy offers a more balanced benefit-risk profile, favoring safer patient outcomes.
Consider adjusting induction regimens based on genetic tumor profiles to optimize treatment effectiveness.
- Cetuximab plus doublet chemotherapy is the only regimen outperforming standard chemotherapy for wild-type KRAS/BRAF tumors in PFS.
Journal Article by Nie G, Li X (…) Lu J et 4 al. in Ann Surg Oncol
© 2026. Society of Surgical Oncology.